Clinical Trial Update: RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib [Phase 3]

View source ↗

Summary

Phase 3 trial comparing everolimus plus best supportive care versus placebo plus best supportive care in metastatic renal cell carcinoma that progressed after s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Renal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2013-01-15